HYUNDAI BIOSCIENCE CO. LTD.
KKRX:0484106,380.00
KRW
+220.00
(+3.57%)
ISIN
KR7048410005
Return %
Stock
S&P 500
1Y
21.52
14.39
3Y
-60.25
81.42
5Y
-43.28
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Geun-Woo Jin
- Full Time Employees
- 67
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 150, Bugahyeon-ro Gimcheon-si SL South Korea 03759
- IPO Date
- Aug 8, 2002
- Website
- hyundaibioscience.com
- Similar Companies
- Business
- Hyundai Bioscience Co., Ltd. (048410.KQ) operates as a clinical-stage biotechnology company focused on developing and commercializing drug delivery system (DDS) platform technologies, including organic-inorganic hybrid bio-fusion solutions for safe and efficient delivery of active ingredients, antiviral agents, and anticancer therapeutics to target sites in the body; its core products and services encompass Vitabrid C12 and Vitabrid CG, premium vitamin C skincare brands utilizing mineral-bound vitamin C for skin brightening, anti-aging, and anti-inflammation; Polytaxel, an anticancer drug candidate for pancreatic cancer and solid tumors; CP-COV03 (Jepti and Zeptee), an oral niclosamide-based broad-spectrum antiviral repurposed from an anthelmintic for COVID-19, dengue fever, and other respiratory viruses with demonstrated rapid viral suppression in phase II/III trials published in Nature Communications; and Penetrium, an innovative ECM-restoration platform addressing pseudo-resistance in oncology and autoimmunity, including rheumatoid arthritis, multiple sclerosis, psoriasis, and Crohn's disease, with Phase 1 approval for prostate cancer and preclinical combination efficacy with gemcitabine achieving 92% tumor inhibition at half-dose. The company, founded in 2000 and headquartered at 3F, 150 Bugahyeon-ro, Seodaemun-gu, Seoul, South Korea, primarily serves the pharmaceuticals and cosmetics sectors with operations centered in South Korea and expanding internationally through clinical trials and partnerships. Recent developments include securing KRW 15-18 billion in funding from Sangsangin entities in 2025 to support pipeline advancement; signing an MOU with DNDi in February 2025 for dengue treatment collaboration on Xafty/CP-COV03; entering a distribution MOU with Vietnam's Vefaco in November 2025 for Zeptee; unveiling Penetrium preclinical results at the AACR-NCI-EORTC conference in Boston in October 2025, highlighting ECM normalization for cancer and autoimmune diseases; advancing seamless phase II/III trials for CP-COV03 in dengue; and presenting oral niclosamide advancements as a metaboli-stable anticancer agent.